Business Wire

ORDRUPGAARD

2.2.2024 16:41:29 CET | Business Wire | Press release

Share
Impressionism and Its Overlooked Women: Berthe Morisot, Mary Cassatt, Marie Bracquemond, Eva Gonzalès and Marie Bashkirtseff

The 150th anniversary of the first impressionist exhibition in Paris in 1874 is celebrated at Ordrupgaard with a magnificent exhibition highlighting the women of impressionism – both behind and in front of the canvas. The exhibition features four female impressionists and their interconnected world of sisters, daughters, and friends through what is incontestably regarded as major works of this period. Due to their gender and class, these artists did not have the same opportunities to depict the pulsating city life enjoyed by their male colleagues. Instead, their focus was on modern life as it unfolded in the home and gardens of Paris and the surrounding area. These intimate motifs were depicted in a radical fashion using bright colours, quick brushstrokes, and a sketch-like technique, which elicited both admiration and indignation from viewers and art critics alike. The exhibition traces the women’s struggle for recognition and a place in art history, examining in more detail their pioneering contribution to the emergence of modern art.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202310892/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Berthe Morisot, The Psyche Mirror, 1876. Museo Nacional Thyssen-Bornemisza. (Photo: Business Wire)

With exceptional loans from around the world, visitors will experience main works by Berthe Morisot (1841–1895) and Mary Cassatt (1844–1926), both of whom are well-known, as well as Marie Bracquemond (1840–1916), Eva Gonzalès (1849–1883), and Marie Bashkirtseff (1858–1884) who, until now, have been off the radar. Marie Bashkirtseff did not belong to the impressionists as such, but in her diary, ’Journal de Marie Bashkirtseff’, published posthumously in 1887, she described the conditions of female artists at the time.

Additionally, the exhibition features key works by Édouard Manet, Edgar Degas, and Pierre-Auguste Renoir inasmuch as they portray female models. The exhibition directs focus at several of the women overlooked by history, immortalised in several of impressionism’s most iconic paintings: from the coloured models in Manet’s and Degas’s pictures to the numerous members and friends perpetuated in the female artists’ canvases. The exhibition seeks not only to examine the technique used to paint these women but also to look at their identity, which unleashes new narratives and overlooked perspectives on impressionism and its actors.

This is the first showing of works by Bashkirtseff and Bracquemond in Denmark and, likewise, bringing together the leading artists in the exhibition is a first of its kind in Scandinavia. We show 57 paintings loaned by 34 lenders from 10 countries.

Press meeting, 9 Feb, 10–12.

https://ordrupgaard.dk/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240202310892/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release

-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe

Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release

The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D

NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release

Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr

MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release

The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity

Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release

New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye